Finch Therapeutics Group, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Finch Therapeutics has filed an amendment to its annual report on Form 10-K to include information typically found in its proxy statement and required certifications.
10-K: Finch Therapeutics Shifts Focus to IP Monetization After Trial Discontinuation, Faces Delisting Risk
Finch Therapeutics has discontinued its Phase 3 clinical trial and is now focusing on monetizing its intellectual property, while also facing potential delisting from the Nasdaq.